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Biomarkers of Inflammation and Fibrosis in Kawasaki Disease
Patients Years After Initial Presentation With Low Ejection Fraction
Shinsuke Hoshino, MD; Chisato Shimizu, MD; Sonia Jain, PhD; Feng He, MS; Adriana H. Tremoulet, MD, MAS; Jane C. Burns, MD
Background-—Coronary artery aneurysms and myocarditis are well-recognized complications of Kawasaki disease (KD) but no
systematic evaluation of the consequences of myocarditis has been performed in the subset presenting with low ejection fraction
(EF). We postulated that more severe myocardial inflammation as evidenced by low EF during the acute phase could lead to late
myocardial fibrosis.
Methods and Results-—We measured the carboxyterminal propeptide of procollagen type I (PIPC), soluble suppressor of
tumorigenicity 2, galectin-3 (Gal-3), growth-differentiation factor-15, and calprotectin by ELISA in late convalescent blood samples
from 16 KD patients who had an EF ≤55% on their initial echocardiogram. Results were compared with samples from sex- and age-
matched KD patients with initial EF >60%. In the univariate analysis, the median Gal-3 and PIPC levels in the low EF group were
significantly higher than those in the normal EF group (Gal-3: low EF 6.216 versus normal EF 4.976 mg/dL P=0.038, PIPC: low EF
427.4 versus normal EF 265.2 mg/dL, P=0.01). In a multivariable analysis, there were significant differences for Gal-3 and PIPC
levels between the low and normal EF groups, adjusting for age, sex, and worst z score.
Conclusions-—Convalescent KD patients with a history of low EF during the acute illness had significantly elevated levels of Gal-3
and PIPC when compared with matched-control KD patients with normal EF. These findings raise concern for myocardial fibrosis as
a potential late sequela of the more severe myocarditis experienced by a subset of KD patients during the acute phase. ( J Am
Heart Assoc. 2020;9:e014569. DOI: 10.1161/JAHA.119.014569.)
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K awasaki Disease (KD) is a self-limited, acute vasculitis ofchildren whose etiology is still unknown.1 The most
significant complications are coronary artery aneurysms
(CAA) that occur in 15% to 25% of untreated patients and
5% of patients treated with intravenous immunoglobulin
(IVIG).2 These important cardiovascular lesions may lead to
ischemic heart disease, myocardial infarction, and sudden
death.3 However, myocarditis is also an important complica-
tion of KD, with subclinical left ventricular (LV) dysfunction
occurring in 50% to 70% of patients in the acute phase.4,5 The
myocarditis improves soon after IVIG treatment6 and
abnormalities of LV function resolve by 1 to 3 years after
KD onset.7,8 The severity of myocarditis is not necessarily
predictive of the severity of coronary artery damage. In 2
series of KD patients presenting with shock and decreased
ejection fraction, only 15 and 43% of patients developed CAA
despite clinical manifestations of myocarditis.9,10 Endomy-
ocardial biopsies in KD patients performed during the
subacute phase demonstrated histological evidence of
myocarditis in all patients despite the absence of clinical
signs of myocarditis.11,12 We postulated that patients initially
presenting with a low EF as a clinical sign of myocardial
inflammation could be at risk for late myocardial fibrosis.
There is controversy regarding how well plasma biomark-
ers predict the histologic finding of myocardial fibrosis.13
From the adult heart failure literature, the carboxyterminal
propeptide of procollagen type I (PIPC) has been used as a
biomarker of myocardial fibrosis.14 Increased serum PIPC
levels correlate with adverse outcomes in heart failure and
myocardial infarction.15,16 Other candidate biomarkers impli-
cated in both myocardial fibrosis and inflammation include
soluble suppressor of tumorigenicity 2 (sST2), galectin-3 (Gal-
3), growth-differentiation factor-15 (GDF-15), and calpro-
tectin.14,17 We previously reported that elevated serum levels
of sST2, a member of the interleukin-1 receptor family and a
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decoy receptor for interleukin-33, are correlated with
impaired myocardial relaxation in acute KD subjects.18 Gal-
3 is a b-galactoside-binding lectin that plays an important
role in inflammation, fibrosis, and cell differentiation19 and
plasma Gal-3 levels are higher in KD subjects with giant
coronary artery aneurysms (CAA) compared with KD subjects
without aneurysms and heathy controls.20 GDF-15 is a
member of the TGF-b superfamily and it is not normally
expressed in the myocardium but is strongly upregulated in
cardiomyocytes by various stressors, including proinflamma-
tory cytokines.21 We recently reported molecular evidence of
on-going inflammation by shotgun proteomics in late conva-
lescent pediatric and adult KD patients with giant CAA.17
These groups showed increased levels of calprotectin, a
marker of inflammation secreted by neutrophils and mono-
cytes. In the present study, we sought to determine if
pediatric KD patients with low EF during their acute illness
have evidence of myocardial inflammation and fibrosis as
evidenced by elevated levels of our candidate biomarkers at
least 1 year after disease onset.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Study materials will not be made available because of limited
availability of samples.
Study Population
We enrolled all patients with KD with an ejection fraction
≤55% by transthoracic echocardiogram during their acute
hospitalization (low EF group) who met American Heart
Association (AHA) guidelines for complete or incomplete KD
and were diagnosed and treated at Rady Children’s Hospital
San Diego between March 1981 and Oct 2018. EF was
measured during the acute illness at the time of diagnosis by
the Teichholz method. Patients <3 years were sedated for
the echocardiogram to ensure accurate measurements.
Because KD patients with giant aneurysms are known to
have elevated levels of biomarkers for inflammation, we
chose for further study only those patients whose worst
coronary artery z score was ≤5 SD units.17,18,20 The worst
coronary artery z score was defined as the largest internal
diameter during the first year after fever onset of the right
coronary artery and left anterior descending coronary artery
normalized for body surface area and expressed as SD units
from the mean as previously described.22 From our database
and biorepository of KD patient blood samples, we matched
the low EF group for sex, age of onset (2 years), age at
sample collection (2 years), and coronary artery z score
(≤2.0 or >2.0) with KD patients with an EF of >60%
(Figure 1). For 2 pairs, the age difference was 4.2 years
and 2.3 years, respectively. If multiple matches were avail-
able, we chose the patient whose onset date was closest to
the low EF patient. The study was reviewed and approved by
the Institutional Review Board at the University of California
San Diego and parents and subjects signed informed consent
or assent documents as appropriate.
KD shock syndrome was defined on the basis of systolic
hypotension for age, a sustained decrease in systolic blood
pressure from baseline of ≥20%, or clinical signs of poor
perfusion, as previously reported.9 IVIG resistance was
defined as persistence of fever (oral or rectal temperature
≥38.0°C) at least 36 hours after the end of the IVIG
infusion.
Sample Collection and Assays
Blood samples were collected at convalescent time points
between 0.9 and 11.3 years after KD onset when all patients
were generally healthy. Blood was collected and separated
immediately by centrifugation and stored at 80°C. We
measured EDTA plasma levels of calprotectin, Gal-3, sST2,
GDF-15, and serum levels of PIPC by ELISA according to the
manufacturer’s instructions: Calprotectin, Gal-3, GDF-15:
R&D Systems, Minneapolis, MN, USA, sST2: Critical
Clinical Perspective
What Is New?
• We measured biomarkers of inflammation and fibrosis in
pediatric patients with Kawasaki disease who initially
presented with low (<55%) ejection fraction but with normal
or mildly dilated coronary arteries.
• Although the ejection fraction normalized in all patients
after treatment, biomarkers of fibrosis were elevated years
after the initial illness.
• No long-term study has previously evaluated markers of
myocardial fibrosis in this subset of Kawasaki disease
patients with initial reduced ejection fraction.
What Are the Clinical Implications?
• The finding of elevated biomarkers of fibrosis in Kawasaki
disease patients who initially presented with severe
myocarditis and reduced ejection fraction raises concern
for late myocardial fibrosis, similar to what has been noted
on adult autopsy studies of Kawasaki disease patients.
• This subset of Kawasaki disease patients may warrant long-
term follow-up and advanced imaging studies to evaluate for
potential myocardial fibrosis, although this is not recom-
mended in the current American Heart Association guide-
lines.
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Diagnostics, San Diego, CA, USA and PIPC: Quidel, San
Diego, CA, USA.
Statistical Analysis
All authors had full access to all the data in the study and
take responsibility for its integrity and the data analysis.
Data were analyzed using R software version 3.5.2 (http://
www.r-project.org) and presented as median and interquar-
tile range. Biomarker levels and interquartile range for
low EF group and matched controls were compared by
paired t-test.
Separate multivariable linear regression models were
fitted for each biomarker measurement as the outcome.
The EF group was the main predictor (low EF versus
normal EF groups), while models were adjusted for age at
onset (in Model 1), age at convalescent phlebotomy (in
Model 2), sex and worst z score. The assumptions of
linear regression were evaluated. P<0.05 was considered
statistically significant.
Results
Characteristics of the Study Population
During the 37-year period of our study, 2079 patients were
registered in our database with echocardiographic data
available from 1556 patients (74.8%). Of these, the EF was
≤55% in 43 patients (2.8%) during the acute phase. Because
of the known association of elevated biomarkers of inflam-
mation with persistent giant CAA, 4 subjects with Zworst
>5.0 were excluded. Late convalescent blood samples were
available for 16 of these 39 patients (41%) with low EF.
(Figure 1).
Clinical and Laboratory Data
There was no significant difference between the low and
normal EF groups in the demographic or clinical features of
KD (Table 1). In the low and normal EF groups, all but 1
patient in the low EF group was diagnosed with complete
KD. In the low EF group, 6 (37.5%) subjects were diagnosed
With echo data
n=1556
Normal EF (>60%)
n=1387
Low EF (≤55%)
n=43 (2.8%)
Excluded subjects with 
worst CA Z-score>5
(including 1 KD shock pt.)
n=4
Low EF with late convalescent 
blood samples 
n=16
Low EF KD subjects matched 1:1 for age 
at convalescent blood draw, sex, age at KD 
onset, and coronary artery status with 
normal EF KD subjects
KD database
1981-2018
n=2079
60% ≥ EF > 55%
n=126
Figure 1. Flow diagram showing low EF study population and matched normal EF KD controls. CA
indicates coronary artery; EF, ejection fraction; KD, Kawasaki disease.
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with KD shock syndrome in the acute phase and required
pressor support and inotropic agents in addition to
standard treatment for KD. The EF normalized to >55% in
all of the low EF subjects between 2- and 31-days post-
treatment (median 6 days, interquartile range 2.0–14.5) and
remained normal for the duration of follow-up. IVIG
resistance was more common in the low EF group
compared with the normal EF group (62.5% and 31.3%,
respectively, P=0.048). Comparison of pre-treatment labo-
ratory data revealed a higher median C-reactive protein
level (20.7 versus 8.5 mg/dL, P=0.008) in the low EF
group.
Biomarker Analysis
Plasma levels of Gal-3, calprotectin, sST2 and GDF-15 and serum
levels of PIPC were measured in all subjects (Figure 2). In the
univariate analysis, themedianGal-3 andPIPC levels in the lowEF
groupwere significantly higher than those in the normal EF group
(Gal-3: low EF 6.2 versus normal EF 5.0 mg/dL P=0.038, PIPC:
low EF 427.4 versus normal EF 265.2 mg/dL, P=0.01). There
was no consistent difference in biomarker levels between the KD
shock patients and other patients within the low EF group.
Two different models were constructed for the multi-
variable analysis. In the first model, EF group (Low EF
Table 1. Characteristics of Kawasaki Disease Patients With Low (≤55%) and Age and Sex Matched Kawasaki Disease Patients With
Normal (>60%) Ejection Fraction on Initial Echocardiogram
Normal EF (EF>60) (n=16) Low EF (EF ≤55%) (n=16) P Value
Characteristic
Age at onset, y 3.6 (2.4–4.5) 3.7 (2.3–5.4) 0.91
% Males 69 63 0.71
Ethnicity, n (%)
Asian 3 (19) 3 (19) 0.52
Black 0 (0) 1 (6)
White 3 (19) 2 (13)
Hispanic 8 (50) 5 (31)
More than one race 2 (12) 5 (31)
Median EF (range) 66 (62–75) 52 (42–55) . . .
EF at time of phlebotomy (range) 71.0 (60.6–80.4) 66.5 (60.1–70.3) 0.12
Illness day of echo with lowest EF, median (range) 7.5 (5–10) 7 (4–14) 0.78
Age at sample collection, y 7.2 (4.7–8.5) 7.8 (5.4–11.1) 0.78
Interval between KD onset and blood sample, y 1.8 (1.1–6.0) 1.7 (1.1–6.1) 0.76
KD shock, n (%) 0 6 (37.5) -
IVIG resistance, n (%) 5 (31.3) 10 (62.5) 0.048*
Zworst score for LAD and RCA, median (range) Zworst score <2.5 1.9 (0.3–2.3) n=6 2.2 (1.4–2.3) n=6 0.79
2.5 ≤Zworst score <5 3.1 (2.5–4.6) n=10 3.3 (2.6–4.7) n=10 0.79
Laboratory data, median (IQR)
WBC, 9103/lL 13.7 (11.2–16.9) 15.5 (10.3–19.9) 0.47
% neutrophils 77.0 (67.5–87.0) 80.0 (70.8–85.0) 0.32
Hemoglobin, g/dL 10.3 (9.75–11.1) 10.1 (9.7–11.2) 0.95
Platelet, 9103/lL 435 (276–506) 282.0 (221.5–352.8) 0.04*
ALT, IU/L 43 (17–108) 60 (43–140) 0.2
GGT, IU/l 60 (15–183) 53 (24–78) 0.76
ESR mm/hr 64 (54–79) 75 (46–136) 0.12
CRP, mg/dL 8.5 (3.3–18.3) 20.7 (13.6–29.5) 0.008*
Zworst was defined as the largest internal CA diameter during the first year after fever onset of the RCA and LAD normalized for body surface area and expressed as standard deviation
units from the mean. ALT indicates alanine aminotransferase; CRP, C-reactive protein; EF, ejection fraction; ESR, erythrocyte sedimentation rate; GGT, c-glutamyl transpeptidase; IVIG,
intravenous immunoglobulin; KD, Kawasaki disease; LAD, left anterior descending coronary artery; NS, not significant; RCA, right coronary artery; WBC, white blood cell.
*Significant P values. Continuous values are median and interquartile range unless otherwise noted.
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versus Normal EF) was the main predictor, adjusting for
age at onset, sex, and Zworst. In the second model, EF
group was again the main predictor, adjusting for age at
time of convalescent phlebotomy, sex, and Zworst. For
both models, there was a significant difference between
the Low EF and Normal EF groups for Gal-3 and PIPC.
This is consistent with the univariate analysis results
(Table 2). Because PIPC levels vary during childhood with
linear growth, we assessed the correlation of PIPC levels
with age of our subjects at the time of convalescent
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Figure 2. Comparison of candidate biomarkers of myocardial fibrosis in late convalescent blood samples
from low EF and normal EF KD subjects. Bars show median and interquartile range. Open circles: KD shock
subjects. EF: ejection fraction; GDF-15, growth-differentiation factor-15; NS, not significant; PIPC,
carboxyterminal propeptide of procollagen type I. P value by paired t test.
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phlebotomy, but no significant relationship emerged
(r2=0.15).
Discussion
In this study, we examined biomarkers of cardiovascular
inflammation and fibrosis in KD subjects with low EF and
normal EF during the acute illness to test the hypothesis
that more severe myocarditis during the acute phase of KD
could predispose to late myocardial fibrosis. We measured
sST2, GDF-15, and PIPC as potential markers of fibrosis,
calprotectin as a measure of inflammation, and Gal-3 as a
marker of both inflammation and fibrosis. Our study revealed
elevated levels of Gal-3 and PIPC but normal levels of
calprotectin at least 1 year after KD onset in the low EF
subjects suggesting the possibility of sub-clinical myocardial
fibrosis.
The biomarkers for this study were specifically chosen to
elucidate either myocardial inflammation or fibrosis. The
calcium binding proteins S100A8 and S100A9 that form the
calprotectin heterodimer are abundant in neutrophils and
have long been recognized as markers of inflammation during
the acute phase of KD.23–27 We recently reported that
calprotectin levels are elevated in pediatric and adult KD
patients with giant CAA years after disease onset.17 In the
present study, there was no significant difference between the
normal EF and low EF groups suggesting the absence of
persistent inflammation in these patients with normal conva-
lescent coronary artery z scores.
Gal-3, a b-galactoside-binding lectin, has been studied as a
potential biomarker for cardiac fibrosis and adverse cardiac
remodeling in heart failure.28,29 Gal-3 is secreted by activated
macrophages and is a mediator of both cardiac inflammation
and fibrosis. In our study, the median Gal-3 level was
increased in the low EF group. Interestingly, Gal-3 has been
detected in a-smooth muscle actin positive myofibroblasts in
the walls of coronary and systemic artery aneurysms and in
the myocardium in hearts from adult KD subjects with giant
aneurysms.20 Gal-3 may also be a therapeutic target as
demonstrated by an ischemia-reperfusion experiment show-
ing reduced myocardial injury in rats fed modified citrus
pectin that inhibits the activity of Gal-3.30
GDF-15 belongs to the transforming growth factor-beta
(TGF-b) superfamily participates in the regulation of inflam-
mation, immune response, apoptosis and cellular prolifera-
tion.31 GDF-15 is weakly expressed by cardiomyocytes under
normal conditions, but is strongly upregulated by inflamma-
tory cytokines and ischemia–reperfusion.21 In atrial fibrillation
and end-stage, non-ischemic dilated cardiomyopathy, the
expression of GDF-15 was related to the degree of cardiac
fibrosis.32
sST2 is a member of the interleukin-1 receptor family and a
decoy receptor for interleukin-33, a member of the inter-
leukin-1 family of cytokines whose expression increases
under inflammatory conditions.33 sST2 is released by car-
diomyocytes and fibroblasts exposed to myocardial strain.34
We previously reported that sST2 levels were significantly
elevated in acute KD subjects compared with convalescent
KD and healthy control subjects,18 suggesting that sST2 may
also be a biomarker of myocardial injury. Some studies
suggest that sST2 may have a direct role in fibrosis or
remodeling.35,36 In rat acute myocardial infarction model,
cardiomyocyte expression of sST2 was upregulated during the
first 4 weeks following acute myocardial infarction and
correlated with the ongoing processes of fibrosis and
inflammation.37
Inflammation and fibrosis are hallmarks of the myocardial
injury during KD. Acute samples were no longer available for
many of these patients. However, in previously published
studies, we reported that acute calprotectin, Gal-3, and sST2
Table 2. Results of Univariate and Multivariable Analyses of Biomarker Levels in Convalescent Blood Samples From KD Subjects
With Normal or Low Ejection Fraction During the Acute Illness
Univariate Analysis (Median [IQR])
(Comparing EF groups)
Multivariable Analysis
(Comparing EF groups)
Model 1 Model 2
Normal EF (>60%) Low EF (≤55%) P Value Estimate Std. Error P Value Estimate Std. Error P Value
Galectin-3 4.98 (3.7–5.7) 6.2 (4.9–7.4) 0.038* 1.64 0.79 0.048* 1.68 0.79 0.042*
Calprotectin 569.3 (336.6–700.8) 540.9 (292.3–1218.7) 0.3603 172.71 174.70 0.33 187.65 168.04 0.27
sST2 30.4 (27.6–35.6) 23.9 (19.8–39.1) 0.982 0.013 4.80 0.998 0.74 4.73 0.88
GDF-15 318.1 (267.3–359.8) 283.5 (258.95–351.5) 0.612 14.52 19.62 0.47 13.93 20.40 0.50
PIPC 265.2 (238.6–312.8) 427.4 (357.1–469.3) 0.0096* 136.61 43.51 0.004* 138.38 38.66 0.001*
Levels of Galectin-3 and PIPC were higher in the low EF subjects in the univariate and in both models of the multivariable analysis that corrected for age of onset (Model 1) and age at
convalescent phlebotomy (Model 2). *Significant values. EF indicates ejection fraction; GDF-15, growth-differentiation factor-1; IQR, interquartile range; PIPC, carboxyterminal propeptide
of procollagen type I.
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levels were elevated compared with the convalescent phase
regardless of EF or coronary artery status.17,18,20 Autopsies of
KD patients with severe myocarditis demonstrate degenera-
tive necrosis of the myocardium associated with marked
inflammatory cell infiltration.38 Myocardial tissues from 29
patients who died within 40 days from KD onset showed
inflammatory cell infiltration in the myocardium and 8 of these
patients had no evidence of CAA.38 Histology of endomy-
ocardial biopsies during the acute phase of KD documented
universal myocardial inflammation and repeat biopsy
>3 years later showed persistence of histopathologic abnor-
malities in the myocardium in many subjects.39 However, the
subsequent evolution of this myocardial inflammation has
largely been addressed through autopsy studies. Severe
myocardial fibrosis in young adults following KD in childhood
has been noted in case reports of explanted hearts from
patients requiring transplant and in small series of autopsy
cases.20,40–42 Histology from autopsies of young adults with
giant aneurysms from KD showed diffuse, bridging fibrosis
that was not confined to the territories supplied by the
affected coronary arteries.42
Imaging studies with cardiac MRI (CMRI) have attempted to
document myocardial fibrosis in convalescent KD patients
with late gadolinium enhancement. To evaluate the extent of
global cardiac fibrosis by non-invasive methods, several
studies have focused on post-contrast CMRI myocardial T1
time to quantify diffuse myocardial fibrosis,43,44 but the
application of these techniques to a KD population has largely
failed to demonstrate abnormalities in the absence of known
ischemic events.45–47 Analysis of CMRI in KD patients with
small to giant aneurysms using a segmental approach
identified regional fibrosis that was related to decreased
myocardial perfusion.48 The use of CMRI to perform feature
tracking demonstrated abnormal longitudinal and circumfer-
ential strain in convalescent KD patients regardless of
coronary artery status.46 As an alternative approach, a study
of 90 Han Chinese KD patients demonstrated abnormal values
of calibrated integrated backscatter by echocardiography as
evidence of myocardial fibrosis irrespective of coronary artery
status.49 Additional evidence for susceptibility to myocardial
fibrosis comes from the Lactobacillus casei cell wall extract
murine model of KD in which isoproterenol chemical stress
induced myocardial fibrosis only in Lactobacillus casei cell wall
extract-exposed mice.50
We recognize both strengths and limitations of our study.
This is the first study to focus on myocardial outcomes as
opposed to coronary artery outcomes in KD patients who
presented with low EF in the initial phase of the disease. The
results raise concerns about the current practice of discharg-
ing KD patients without aneurysms from care following the 4-
week visit as outlined in the current AHA guidelines, which
would have applied to 6 patients in our low EF group.2 The
limitations of the study include the cross-sectional design
with a small sample size and as such, the study should be
viewed as exploratory. Validation is required with longitudinal
data from the same patients over time to understand if the
process of myocardial fibrosis is progressive or static. In
addition, imaging studies including CMRI with T1 mapping
should be included to provide further evidence of subclinical
myocardial fibrosis. Measurement of the myocardial perfusion
reserve index coupled with the biomarker analysis could help
to delineate if fibrosis is related to microvascular insufficiency
as has been suggested by previous studies.45,51 If findings
from this study are validated by imaging, therapeutic interven-
tion to prevent future myocardial fibrosis may be warranted.
Conclusions
KD patients presenting with isolated low EF with normal
coronary artery dimensions during the acute phase of their
illness may be at risk for myocardial fibrosis as a late sequela.
Further studies are needed to determine the dynamics of these
biomarker levels over time and to link these data to imaging
studies of structural changes in the myocardium. This study
identifies a subset of KD patients who may warrant additional
surveillance in the late convalescent period, although this is
not a recommendation in the current AHA guidelines.
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